Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human interferon alpha-1b inhalation to prevent severe complications in children with hand, foot and mouth disease
ChiCTR-PRC-12002098Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Sep 2014
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recombinant human interferon alpha-1b (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Rate of severe hand, foot and mouth disease. Started Sep 2014; status: completed.
02
Drugs
recombinant human interferon alpha-1b
Beyond the preview
Go deeper on ChiCTR-PRC-12002098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-PRC-12002098.